Neurocrine Biosciences reports Q1 2026 sales $811M (up 44%); agrees to acquire Soleno Therapeutics for $2.9B

NEUROCRINE BIOSCIENCES INC

2026-Q1 EPS reported $1.91 revenue$814,500,000

Net product sales of $811.0M in Q1 2026, a 44% increase year-over-year, led by INGREZZA ($656.9M) and CRENESSITY ($153.3M).
Definitive agreement to acquire Soleno Therapeutics for $53.00 per share ($2.9B equity value), expected to close in Q2 2026.
Initiated Phase 2 study of NBI-1117570 (dual M1/M4 agonist) for schizophrenia and Phase 1 study of NBIP-’2118 (CRF2 agonist) for obesity.
Reaffirmed full-year 2026 INGREZZA net sales guidance of $2.7-$2.8 billion and total cash of $2.65 billion at March 31, 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.